Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 482 followers
Latest posts
Last updated about 2 hours ago
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
about 2 hours ago
Q4 and full year 2024 performance highlights
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
5 days ago
Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete...
Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
8 days ago
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing.
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
8 days ago
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency
9 days ago
Over 25 million people in Europe have received GSK’s shingles vaccine since...
GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
9 days ago
Collaboration unites GSK and Oxford’s complementary expertise in the science of the...
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
16 days ago
Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer...
GSK enters agreement to acquire IDRx, Inc.
23 days ago
Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers
GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA
26 days ago
If approved, the new presentation will offer a convenient administration option to...
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
29 days ago
Regulatory designation based on promising early data in this rare bone cancer.
GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
about 1 month ago
This is the third indication for mepolizumab in China for an IL-5...
GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer
about 2 months ago
GSK announces headline results from the FIRST-ENGOT-OV44 phase III trial.